260 related articles for article (PubMed ID: 14722073)
41. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter.
Métivier R; Penot G; Hübner MR; Reid G; Brand H; Kos M; Gannon F
Cell; 2003 Dec; 115(6):751-63. PubMed ID: 14675539
[TBL] [Abstract][Full Text] [Related]
42. Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway.
Mishra SK; Talukder AH; Gururaj AE; Yang Z; Singh RR; Mahoney MG; Francí C; Vadlamudi RK; Kumar R
J Biol Chem; 2004 Jul; 279(31):32709-15. PubMed ID: 15169784
[TBL] [Abstract][Full Text] [Related]
43. Contribution of HDAC3 to transcriptional repression by the human papillomavirus 31 E8^E2 protein.
Dreer M; Blondzik S; Straub E; Iftner T; Stubenrauch F
J Gen Virol; 2020 Jul; 101(7):751-759. PubMed ID: 32421493
[TBL] [Abstract][Full Text] [Related]
44. Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
Giamarchi C; Chailleux C; Calligé M; Rochaix P; Trouche D; Richard-Foy H
Biochim Biophys Acta; 2002 Oct; 1578(1-3):12-20. PubMed ID: 12393183
[TBL] [Abstract][Full Text] [Related]
45. A feed-forward repression mechanism anchors the Sin3/histone deacetylase and N-CoR/SMRT corepressors on chromatin.
Vermeulen M; Walter W; Le Guezennec X; Kim J; Edayathumangalam RS; Lasonder E; Luger K; Roeder RG; Logie C; Berger SL; Stunnenberg HG
Mol Cell Biol; 2006 Jul; 26(14):5226-36. PubMed ID: 16809761
[TBL] [Abstract][Full Text] [Related]
46. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
47. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
48. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
49. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.
Bartella V; Rizza P; Barone I; Zito D; Giordano F; Giordano C; Catalano S; Mauro L; Sisci D; Panno ML; Fuqua SA; Andò S
Breast Cancer Res Treat; 2012 Jul; 134(2):569-81. PubMed ID: 22622808
[TBL] [Abstract][Full Text] [Related]
51. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
[TBL] [Abstract][Full Text] [Related]
52. Dynamic histone acetylation/deacetylation with progesterone receptor-mediated transcription.
Aoyagi S; Archer TK
Mol Endocrinol; 2007 Apr; 21(4):843-56. PubMed ID: 17227884
[TBL] [Abstract][Full Text] [Related]
53. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.
Shang Y; Hu X; DiRenzo J; Lazar MA; Brown M
Cell; 2000 Dec; 103(6):843-52. PubMed ID: 11136970
[TBL] [Abstract][Full Text] [Related]
54. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters.
Kininis M; Chen BS; Diehl AG; Isaacs GD; Zhang T; Siepel AC; Clark AG; Kraus WL
Mol Cell Biol; 2007 Jul; 27(14):5090-104. PubMed ID: 17515612
[TBL] [Abstract][Full Text] [Related]
55. Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen.
Hao H; d'Alincourt-Salazar M; Kelley KM; Shatnawi A; Mukherjee S; Shah YM; Ratnam M
Oncogene; 2007 Dec; 26(57):7872-84. PubMed ID: 17599049
[TBL] [Abstract][Full Text] [Related]
56. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex.
Kai L; Samuel SK; Levenson AS
Int J Cancer; 2010 Apr; 126(7):1538-48. PubMed ID: 19810103
[TBL] [Abstract][Full Text] [Related]
57. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells.
Monroe DG; Secreto FJ; Subramaniam M; Getz BJ; Khosla S; Spelsberg TC
Mol Endocrinol; 2005 Jun; 19(6):1555-68. PubMed ID: 15802376
[TBL] [Abstract][Full Text] [Related]
58. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
Castro-Rivera E; Safe S
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
[TBL] [Abstract][Full Text] [Related]
59. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex.
Suzuki A; Sanda N; Miyawaki Y; Fujimori Y; Yamada T; Takagi A; Murate T; Saito H; Kojima T
J Biol Chem; 2010 Apr; 285(18):13444-53. PubMed ID: 20200160
[TBL] [Abstract][Full Text] [Related]
60. In vivo repression of an erythroid-specific gene by distinct corepressor complexes.
Rietveld LE; Caldenhoven E; Stunnenberg HG
EMBO J; 2002 Mar; 21(6):1389-97. PubMed ID: 11889044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
